Results 201 to 210 of about 34,342 (262)

Adenoviral Inciting Antigen and Somatic Hypermutation in VITT. [PDF]

N Engl J Med
Wang JJ, Schönborn L, Warkentin TE, Müller L, Thiele T, Ulm L, Völker U, Ameling S, Franzenburg S, Kaderali L, Tzvetkova A, Colella A, Chataway T, Tan CW, Armour B, Troelnikov A, Rutten L, McCluskey J, Zahn R, Gordon TP, Greinacher A.   +20 more
europepmc   +1 more source

A covalent peptide engager approach to equip immunotherapeutic monoclonal and pan IgG serum antibodies with new tumour‐targeting function

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Site‐specific antibody modification is a useful chemical strategy to elaborate antibody therapeutic function. Conventional lysine‐ or cysteine‐based conjugation methods generate heterogeneous products, while protein engineering approaches are resource‐intensive.
Karolina Krygier, Sandra Szu‐Wei Hwang, Anthony F. Rullo   +2 more
wiley   +1 more source

ImmunoMatch learns and predicts cognate pairing of heavy and light immunoglobulin chains. [PDF]

Nat Methods
Guo D, Dunn-Walters DK, Fraternali F, Ng JCF.   +3 more
europepmc   +1 more source

The role of macrophage migration inhibitory factor (MIF) in the pathogenesis and progression of cardiovascular disease

British Journal of Pharmacology, EarlyView.
Abstract Cardiovascular disease (CVD) remains the leading global cause of death, driven by complex mechanisms, in which chronic inflammation plays a central role. Inflammatory pathways contribute to all stages of CVD, from endothelial dysfunction and plaque formation to erosion, rupture and myocardial injury.
Shreya Mahabhashyam, James Harris, Jürgen Bernhagen, Antony Vinh, Katrina M. Mirabito Colafella   +4 more
wiley   +1 more source

Serum free light chain concentration and ratio-based criterion for myeloma-defining event, in its current version, is untenable. [PDF]

Br J Haematol
Singh G.
europepmc   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, EarlyView.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

CNS Involvement of Multiple Myeloma-A Case Series and Narrative Literature Review. [PDF]

J Clin Med
Andrunache A, Himcinschi ME, Barbu S, Zidaru LE, Alexa D, Popescu M, Apuscaroaie SM, Popa DC, Ursuleac I, Coriu D, Badelita SN.   +10 more
europepmc   +1 more source

Targeting PCSK9 in Vascular Smooth Muscle Cells: An Effective Strategy to Suppress Ferroptosis and Attenuate Abdominal Aortic Aneurysm Progression

Cell Proliferation, EarlyView.
PCSK9 aggravates AAA by promoting ferroptosis in VSMCs. In the pathological AAA environment, PCSK9 upregulation triggers ferritinophagy‐dependent degradation of FTH1, leading to Fe2+ release, triggering lipid peroxidation and ferroptosis, exacerbating AAA.
Mengdie Xia, Man Li, Yanyu Chen, Jialin Chen, Yuting Cui, Xi‐Long Zheng, Jing Yang, Bingzhao Li, Xiaofeng Ma, Miao Liu, Gang Fan, Juan Peng, Xiaoyan Dai, Zhihan Tang   +13 more
wiley   +1 more source

Longitudinal evolution of rheumatoid factor-expressing lymphoma precursors in a patient with Sjögren's disease. [PDF]

J Transl Autoimmun
Lee AYS, Wang JJ, Brown DA, Reed JH.
europepmc   +1 more source

Unfavourable H-CDR3 Loops in preB Cells Lead to Highly Expanded Plasma Cell Clones. [PDF]

Eur J Immunol
Aranburu A, Engström E, Demitz-Helin E, Scheffler JM, Camponeschi A, Sundell T, Ni Z, Mårtensson IL.   +7 more
europepmc   +1 more source